BCR-ABL1转录本倍增时间可预测慢性髓性白血病停用伊马替尼后无治疗缓解失败
每月评估DT有助于识别无治疗缓解失败高风险患者及可减少监测频率的低风险患者。
要点
- 每月评估BCR-ABL1转录本DT有助于分层管理无治疗缓解患者。
核心结论
- 停用伊马替尼后每月评估BCR-ABL1转录本倍增时间可预测无治疗缓解失败,高风险组分子学复发风险最高。
研究设计与样本
- 研究纳入131例慢性期慢性髓性白血病患者,停用伊马替尼后6个月内每月计算BCR-ABL1转录本倍增时间。
临床怎么用
- 每月评估BCR-ABL1转录本DT有助于识别无治疗缓解失败高风险患者,及时干预。
- DT≤0的低风险患者可考虑减少每月分子学监测频率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The doubling time (DT) of the BCR-ABL1 quantitative polymerase chain reaction (qPCR) transcript level reflects the re-growing fraction of leukaemic cells after discontinuation of tyrosine kinase inhibitor (TKI). The present study analyzed monthly DT within six months after imatinib discontinuation in 131 patients. Monthly DT was calculated as x = ln(2)/K, where x is the DT and K is the fold BCR-ABL1 change from the previous value divided by the number of days between each measurement. The optimal DT value was determined as 12·75 days at two months using a recursive partitioning method. The patients were stratified into three groups: the high-risk group (DT<12·75 days but >0, with rapidly proliferating chronic myeloid leukaemia (CML) cells; n = 26) showed the lowest molecular relapse-free survival (mRFS) of 7·7% at 12 months, compared to 53·6% in the intermediate-risk group (DT≥12·75 days, with slowly proliferating CML cells; n = 16) or 90·0% in the low-risk group (DT≤0, i.e., without proliferating CML cells; n = 71; P < 0·001). Monthly assessment of DT helps identify high-risk patients for treatment-free remission failure with an imminent risk of molecular recurrence, and to define low-risk patients who can be spared the frequent monitoring of monthly molecular tests.
引用
- Kim DDH, Kim TS, Atenafu EG, et al. BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase. Br J Haematol. 2021. PMID: 34496035. doi:10.1111/bjh.17807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。